| Literature DB >> 33198772 |
Guangli Sun1, Zheng Li1, Zhongyuan He1, Weizhi Wang1, Sen Wang1, Xing Zhang1, Jiacheng Cao1, Penghui Xu1, Haixiao Wang1, Xiaoxu Huang1, Yiwen Xia1, Jialun Lv1, Zhe Xuan1, Tianlu Jiang1, Lang Fang1, Jing Yang1, Diancai Zhang1, Hao Xu1, Zekuan Xu2,3.
Abstract
BACKGROUND: Cisplatin (CDDP) is the first-line chemotherapy for gastric cancer (GC). The poor prognosis of GC patients is partially due to the development of CDDP resistance. Circular RNAs (circRNAs) are a subclass of noncoding RNAs that function as microRNA (miRNA) sponges. The role of circRNAs in CDDP resistance in GC has not been evaluated.Entities:
Keywords: CircMCTP2; Cisplatin; GC; MTMR3; miR-99a-5p
Mesh:
Substances:
Year: 2020 PMID: 33198772 PMCID: PMC7670601 DOI: 10.1186/s13046-020-01758-w
Source DB: PubMed Journal: J Exp Clin Cancer Res ISSN: 0392-9078
Fig. 1CircMCTP2 expression is downregulated in CDDP-resistant GC tissues and cells. a Heatmap of circular RNAs downregulated in BGC823CDDP and SGC7901CDDP cells compared to CDDP-sensitive GC cells. b qRT-PCR-based identification of circular RNAs that were decreased in CDDP-resistant GC tissues. c Expression of circMCTP2 in CDDP-resistant and CDDP-sensitive GC cells by qRT-PCR. d Confirmation of head-to-tail splicing of circMCTP2 with Sanger sequencing. e RT-PCR-based detection of back-spliced and linear MCTP2 in cDNA with or without RNase R and genomic DNA (gDNA). f CircMCTP2 and MCTP2 mRNA were treated with RNase R to detect their stability. g Results of actinomycin D assay. h FISH-based validation of preferential localization of circMCTP2 to the GC cell cytoplasm. i qRT-PCR-based confirmation of circMCTP2 localization mainly within the GC cell cytoplasm. (*p < 0.05, **p < 0.01. Data are expressed as the means ± SDs)
Expression of circMCTP2 in human gastric cancer and the clinicopathological characteristics of the patients’
| Characteristics | Number | circMCTP2 expression | ||
|---|---|---|---|---|
| High group | Low group | |||
| Age (years) | ||||
| ≥ 60 | 61 | 32 | 29 | 0.539 |
| < 60 | 39 | 18 | 21 | |
| Gender | ||||
| Male | 68 | 32 | 36 | 0.391 |
| Female | 32 | 18 | 14 | |
| Size (cm) | ||||
| ≥ 3(cm) | 57 | 21 | 36 | 0.002** |
| < 3(cm) | 43 | 29 | 14 | |
| Stage | ||||
| II | 42 | 26 | 16 | 0.043* |
| III | 58 | 24 | 34 | |
| T grade | ||||
| T1 + T2 | 36 | 23 | 13 | 0.037* |
| T3 + T4 | 64 | 27 | 37 | |
| Lymph node metastasis | ||||
| N1-N3 | 87 | 41 | 46 | 0.137 |
| N0 | 13 | 9 | 4 | |
| CDDP chemosensitivity | ||||
| Sensitive | 75 | 48 | 27 | < 0.001** |
| Resistant | 25 | 2 | 3 | |
*p < 0.05 and **p < 0.01 Statistically significant difference
Fig. 2Overexpression of circMCTP2 facilitates the sensitivity of CDDP-resistant GC cells in vitro. a and b Reduction in CDDP-resistant GC cell viability by elevated expression of circMCTP2. c Impairment of the colony-forming ability of BGC823CDDP cells in response to cisplatin treatment after circMCTP2 overexpression. d CircMCTP2-mediated decrease in colony formation by SGC7901CDDP cells in the presence of cisplatin. e Assessment of DNA synthesis of BGC823CDDP and SGC7901CDDP cells transfected with NC and lentivirus-circMCTP2 in the presence of cisplatin. f and g Flow cytometric analysis of the apoptosis of CDDP-resistant GC cells treated with cisplatin. h Detection of apoptosis-related proteins by western blotting in BGC823CDDP and SGC7901CDDP cells. CDDP treatment: 12 μM for 48 h in BGC823CDDP cells and 6 μM for 48 h in SGC7901CDDP cells. (*p < 0.05, **p < 0.01. Data are expressed as the means ± SDs)
Fig. 3CircMCTP2 represses autophagy in CDDP-resistant GC cells. a Expression of p62 protein was lower in CDDP-resistant GC patients than in CDDP-sensitive GC patients. b Expression levels of p62 were detected in GC tissues by western blotting. c-f GFP/mRFP-LC3 dots were observed and counted by confocal microscopy. g Protein levels of Beclin1, p62, and LC3-II were examined by western blotting. h and i The autophagic microstructure of CDDP-resistant GC cells was observed by transmission electron microscopy. CDDP treatment: 12 μM for 48 h in BGC823CDDP cells and 6 μM for 48 h in SGC7901CDDP cells. (*p < 0.05, **p < 0.01. Data are expressed as the means ± SDs)
Fig. 4CircMCTP2 serves as a miRNA sponge of miR-99a-5p. a Candidate miRNAs predicted to be the potential binding targets of circMCTP2. b qRT-PCR analysis to examine the expression of circMCTP2 in BGC823CDDP and SGC7901CDDP cell lysates. c and d qRT-PCR analysis to examine the expression of candidate miRNAs after pull-down assays. e Analysis of luciferase activity in BGC823CDDP and SGC7901CDDP cells transfected with miR-NC or miR-99a-5p mimics and WT or mutant circMCTP2. f CircMCTP2 and miR-99a-5p localization to the cytoplasm of CDDP-resistant GC cells by FISH assay. g MiR-99a-5p upregulation in CDDP-resistant GC tissues by qRT-PCR. h MiR-99a-5p upregulation in CDDP-resistant GC cells by qRT-PCR. i Lack of effect of miR-99a-5p overexpression or knockdown on the expression of circMCTP2. (*p < 0.05, **p < 0.01. Data are expressed as the means ± SDs)
Fig. 5MTMR3 is a direct target of miR-99a-5p. a Potential binding site of miR-99a-5p for MTMR3 as predicted by TargetScan. b Luciferase reporter assay for determining whether miR-99a-5p could bind to wt-MTMR3–3’UTR or mut-MTMR3–3’UTR. c Pull-down assay confirmation of MTMR3 as a target of miR-99a-5p. d RIP assay confirmation of the interaction between miR-99a-5p and MTMR3. e qRT-PCR analysis revealing that downregulation of miR-99a-5p could increase the expression levels of MTMR3. f Increased protein expression levels of MTMR3 after knockdown of miR-99a-5p. g qRT-PCR analysis of the expression of MTMR3 CDDP-sensitive and CDDP-resistant GC cells. h MTMR3 detection in CDDP-resistant and CDDP-sensitive GC cells by western blotting. i MTMR3 expression detection using qRT-PCR in CDDP-sensitive and CDDP-resistant GC tissues. j Negative correlation between MTMR3 expression and miR-99a-5p expression. k and l qRT-PCR analysis showing that MTMR3 expression was increased by circMCTP2 but reversed by overexpression of miR-99a-5p. m and n Diminishment of the promotive effect of circMCTP2 on the protein expression of MTMR3 by the overexpression of miR-99a-5p. (*p < 0.05, **p < 0.01. Data are expressed as the means ± SDs)
Fig. 6The effects of circMCTP2 can be reversed by the knockdown of MTMR3. a The expression levels of MTMR3 in BGC823CDDP and SGC7901CDDP cells after transfection with lentivirus-shMTMR3 were determined by qRT-PCR. b Protein expression levels of MTMR3 in BGC823CDDP and SGC7901CDDP cells were detected by western blotting. c and d Effects of circMCTP2 on cell proliferation and colony formation by BGC823CDDP cells were reversed by the knockdown of MTMR3. e and f Decreased cell proliferation and colony-forming ability of SGC7901CDDP cells caused by circMCTP2 were restored by the knockdown of MTMR3. g MTMR3 knockdown reversed the effects of circMCTP2 on cell viability. h Expression levels of apoptotic proteins were examined by western blotting. i and j Flow cytometric analysis was performed to determine whether shMTMR3 could reverse the effect of circMCTP2 on the apoptosis of BGC823CDDP and SGC7901CDDP cells. CDDP treatment: 12 μM for 48 h in BGC823CDDP cells and 6 μM for 48 h in SGC7901CDDP cells. (*p < 0.05, **p < 0.01. Data are expressed as the means ± SDs)
Fig. 7The effect of circMCTP2 on autophagy is reversed by the downregulation of MTMR3. a-d Confocal microscopy analysis showing the accumulation of GFP/mRFP-LC3 dots. e and f Western blotting showing the expression levels of Beclin1, p62, and LC3-II proteins. g and h TEM analysis showing the autophagic microstructure in CDDP-resistant GC cells. CDDP treatment: 12 μM for 48 h in BGC823CDDP cells and 6 μM for 48 h in SGC7901CDDP cells. (*p < 0.05, **p < 0.01. Data are expressed as the means ± SDs)
Fig. 8CircMCTP2 sensitizes GC cells to CDDP in vivo. a-d CircMCTP2 suppressed the growth of xenograft tumors with CDDP treatment. e Xenograft tumor weights were measured. f CircMCTP2 expression was detected by qRT-PCR in xenograft tumors. g The percentage of Ki67-positive cells in xenograft tumors was measured. h TUNEL assay was performed to determine the apoptosis of GC cells in nude mouse tumors. i, j MTMR3 protein expression in xenograft tumors was examined by IHC and western blotting. k The expression levels of circMCTP2 and miR-99a-5p were detected by FISH assay in CDDP-resistant and CDDP-sensitive GC tissues. l The results of IHC revealed that MTMR3 was downregulated in CDDP-resistant GC tissues. (*p < 0.05, **p < 0.01. Data are expressed as the means ± SDs)